Waters Announced the FDA Clearance of the Most Comprehensive At-Home Cervical Cancer Screening Tool, the Onclarity HPV Self-Collection Kit and FDA-Approved HPV Assay
On 08 April 2026, Waters Corporation announced that the U.S. Food and Drug Administration had cleared the Onclarity HPV Self-Collection Kit and approved the BD Onclarity HPV Assay with extended genotyping for at-home use, marking a major advancement in improving access to cervical cancer screening. This milestone aimed to reduce barriers that had previously prevented many individuals from undergoing routine screening.
Cervical cancer, largely preventable through regular screening and early detection...
